H. Lundbeck A/s

This study tests an experimental drug called Lu AF82422 in 64 people with multiple system atrophy (MSA), a rare and serious brain disorder. The goal is to see if the drug can slow down the disease's progression compared to a placebo. Participants receive either the drug or a plac…

This phase 3 trial tests an experimental drug called amlenetug in 401 people with multiple system atrophy (MSA), a rare and rapidly worsening brain disorder. The study aims to see if the drug can slow the disease's progression and improve survival. Participants receive either the…

This early-stage trial tests a drug called Lu AG22515 in 20 adults with moderate-to-severe thyroid eye disease, an autoimmune condition that causes eye swelling and bulging. The main goal is to see if the drug reduces bulging over 24 weeks. Researchers will also measure how the d…

This study tests a new medication called Lu AG09222 to see if it can prevent migraines in people who have already tried 1 to 4 other preventive treatments without success. About 874 participants will receive either the drug or a placebo to find the best dose. The main goal is to …

This study tests whether eptinezumab can reduce migraine days and improve quality of life in 164 adults who previously did not get enough relief from other CGRP-targeting migraine drugs. Participants receive the drug and report changes in migraine frequency and severity over time…

This study follows 90 people with Multiple System Atrophy (MSA) in China and Europe to track how the disease progresses over 12 months. Researchers will use regular check-ups, brain scans, and blood tests to measure changes. The goal is to better understand MSA and improve future…